Research Briefs: Medtronic’s New Renal Denervation Trial; CPAP Combats Hypertension; Prosigna Breast Cancer Assay
This article was originally published in The Gray Sheet
Medtronic launches the SYMPLICITY HTN-4 trial in moderate hypertension patients. Trial shows CPAP for sleep-apnea patients can also improve blood pressure. The information provided by NanoString’s breast cancer assay could help patients avoid unnecessary chemotherapy.
You may also be interested in...
Patient-recruitment challenges have led St. Jude to halt a U.S. clinical trial of its EnligHTN renal denervation system. The company says it is working with FDA to design a new trial.
Medtronic Renal Denervation System Provides Durable Blood Pressure Benefits In Longest Trial To Date
The latest results from Medtronic’s SYMPLICITY HTN-2 trial show that patients treated for severe hypertension with the company’s Symplicity radio frequency renal denervation system showed a sustained reduction in blood pressure. The firm also announced the start of a renal denervation trial in patients with moderate hypertension.
An estimated 15 million Americans have obstructive sleep apnea severe enough to warrant treatment, but this field has been chronically underserved by traditional continuous positive airway pressure systems that are inconvenient and uncomfortable to use. To address this problem, CPAP manufacturers are making design improvements to optimize comfort and compliance; at the same time, promising new technologies are emerging – including neurostimulation devices for OSA – that could help reshape the future management of this often overlooked, but serious disorder.